当前位置: X-MOL 学术J. Clin. Invest. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19
The Journal of Clinical Investigation ( IF 13.3 ) Pub Date : 2021 , DOI: 10.1172/jci151788
Shanna A Arnold Egloff 1, 2 , Angela Junglen 1, 2, 3 , Joseph Sa Restivo 2 , Marjorie Wongskhaluang 2 , Casey Martin 1, 2, 3 , Pratik Doshi 1, 2, 3 , Daniel Schlauch 1, 3 , Gregg Fromell 1, 2 , Lindsay E Sears 1, 2 , Mick Correll 1, 3 , Howard A Burris 1, 2 , Charles F LeMaistre 1, 2
Affiliation  

BACKGROUND. Evidence supporting convalescent plasma (CP), one of the first investigational treatments for coronavirus disease 2019 (COVID-19), has been inconclusive, leading to conflicting recommendations. The primary objective was to perform a comparative effectiveness study of CP for all-cause, in-hospital mortality in patients with COVID-19.

中文翻译:

恢复期血浆与 COVID-19 住院患者的死亡率降低和临床轨迹改善有关

背景。支持恢复期血浆 (CP) 是 2019 年冠状病毒病 (COVID-19) 的首批研究性治疗方法之一的证据尚无定论,导致建议相互矛盾。主要目的是对 CP 对 COVID-19 患者的全因住院死亡率进行比较有效性研究。
更新日期:2021-10-17
down
wechat
bug